

Press Release

for Immediate Release

Q3FY26 Revenue from operations at INR 13,879 Mn up 22% YoY, EBITDA at INR 3,081 Mn up 34% YoY, PBT at INR 2,022 Mn up 32% YoY, PAT at INR 1,502 Mn up 28% YoY.

Hyderabad, India, January 23, 2026: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter ended December 31, 2025.

Financial Summary (All numbers in INR Mn)

QUARTERLY CONSOLIDATED FINANCIALS	Q3FY26	Q2FY26	Growth (QoQ)	Q3FY25	Growth (YoY)
Revenue from Operations	13,879	12,970	7%	11,377	22%
EBITDA	3,081	2,782	11%	2,303	34%
EBITDA %	22%	21%		20%	
PBT	2,022	1,759	15%	1,528	32%
PAT	1,502	1,306	15%	1,176	28%
PAT %	11%	10%		10%	

Financial and Business Summary for Q3FY26

- Revenue from Operations of Q3FY26 stood at INR 13,879 Mn, a growth of 22% YoY driven by Finished Dosages (FD) segment in North America and Europe
- Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptides/ CDMO contribute 76%, 11%, 11% and 2% of revenue from operations respectively for Q3FY26.
- ROCE is at 16.8% (Post Acquisition of Senn Chemicals AG) as compared to 16.4% YoY.
- Net debt stood at INR 10,151 Mn and Net debt to EBITDA at 0.91x.

Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “Q3 has been one of our strongest quarters, reflecting disciplined execution of strategic growth initiatives and we are well positioned for sustained growth momentum. Our strong financial performance, on-going R&D investments, combined with advances in ESG stewardship and our expanding global supply footprint, reinforces our commitment to building a resilient, innovation-led pharmaceutical platform that delivers long-term value for all stakeholders.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ pcountries with offices across India, US, and Switzerland. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

Safe Harbor

This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:	
Granules IR Desk investorrelations@granulesindia.com	Chaitanya Tummala Company Secretary chaitanya.tummala@granulesindia.com